Related Experiment Video
Updated: Jun 15, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prevalence of prostate cancer in end-stage renal disease patients
Toshiro Kamata1, Kiyohide Fushimi
1Department of Health Care Informatics, Tokyo Medical and Dental University, Graduate School of Medicine, Tokyo, Japan. tkamata.hci@tnd.ac.jp
Aims:
We aimed to assess the prevalence of prostate cancer in end-stage renal disease (ESRD) patients by a large-scale, multicentric and prospective study, and to show the difference between ESRD patients and normal healthy subjects.
Methods:
The level of serum prostate-specific antigen (PSA) was measured in 724 male ESRD patients undergoing dialysis. Those patients whose serum PSA level was over 4.0 ng/ml underwent a second screening test. After diagnosis, the prevalence of prostate cancer was subsequently calculated following adjustments by logistic-regression analysis. The prevalence of prostate cancer was also assessed in three control groups who had undergone health checks.
Results:
The prevalence of prostate cancer in ESRD patients was found to be 1.4%. Those of the control groups (after correction for age) were 0.4, 1.4 and 0.8%. The odds ratios were 3.49, 0.96 and 1.71.
Conclusion:
The prevalence of prostate cancer in ESRD patients was equal or higher compared with that of normal healthy subjects. The result strongly indicates that the use of the serum PSA assay contributes to the early detection of prostate cancer in ESRD patients.
Related Concept Videos
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:21Nursing Assessment of the Genitourinary System I: Health History
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:28Diabetic Nephropathy